Search

Your search keyword '"Wang Wenxian"' showing total 1,040 results
Start Over Author "Wang Wenxian"
1,040 results on '"Wang Wenxian"'

155. Supplementary Figures 1-5 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Author

Rhyasen, Garrett W., primary, Hattersley, Maureen M., primary, Yao, Yi, primary, Dulak, Austin, primary, Wang, Wenxian, primary, Petteruti, Philip, primary, Dale, Ian L., primary, Boiko, Scott, primary, Cheung, Tony, primary, Zhang, Jingwen, primary, Wen, Shenghua, primary, Castriotta, Lillian, primary, Lawson, Deborah, primary, Collins, Michael, primary, Bao, Larry, primary, Ahdesmaki, Miika J., primary, Walker, Graeme, primary, O'Connor, Greg, primary, Yeh, Tammie C., primary, Rabow, Alfred A., primary, Dry, Jonathan R., primary, Reimer, Corinne, primary, Lyne, Paul, primary, Mills, Gordon B., primary, Fawell, Stephen E., primary, Waring, Michael J., primary, Zinda, Michael, primary, Clark, Edwin, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

156. Supplementary Table 2 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Author

Rhyasen, Garrett W., primary, Hattersley, Maureen M., primary, Yao, Yi, primary, Dulak, Austin, primary, Wang, Wenxian, primary, Petteruti, Philip, primary, Dale, Ian L., primary, Boiko, Scott, primary, Cheung, Tony, primary, Zhang, Jingwen, primary, Wen, Shenghua, primary, Castriotta, Lillian, primary, Lawson, Deborah, primary, Collins, Michael, primary, Bao, Larry, primary, Ahdesmaki, Miika J., primary, Walker, Graeme, primary, O'Connor, Greg, primary, Yeh, Tammie C., primary, Rabow, Alfred A., primary, Dry, Jonathan R., primary, Reimer, Corinne, primary, Lyne, Paul, primary, Mills, Gordon B., primary, Fawell, Stephen E., primary, Waring, Michael J., primary, Zinda, Michael, primary, Clark, Edwin, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

157. Data from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Author

Rhyasen, Garrett W., primary, Hattersley, Maureen M., primary, Yao, Yi, primary, Dulak, Austin, primary, Wang, Wenxian, primary, Petteruti, Philip, primary, Dale, Ian L., primary, Boiko, Scott, primary, Cheung, Tony, primary, Zhang, Jingwen, primary, Wen, Shenghua, primary, Castriotta, Lillian, primary, Lawson, Deborah, primary, Collins, Michael, primary, Bao, Larry, primary, Ahdesmaki, Miika J., primary, Walker, Graeme, primary, O'Connor, Greg, primary, Yeh, Tammie C., primary, Rabow, Alfred A., primary, Dry, Jonathan R., primary, Reimer, Corinne, primary, Lyne, Paul, primary, Mills, Gordon B., primary, Fawell, Stephen E., primary, Waring, Michael J., primary, Zinda, Michael, primary, Clark, Edwin, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

158. Supplementary Table 3 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Author

Rhyasen, Garrett W., primary, Hattersley, Maureen M., primary, Yao, Yi, primary, Dulak, Austin, primary, Wang, Wenxian, primary, Petteruti, Philip, primary, Dale, Ian L., primary, Boiko, Scott, primary, Cheung, Tony, primary, Zhang, Jingwen, primary, Wen, Shenghua, primary, Castriotta, Lillian, primary, Lawson, Deborah, primary, Collins, Michael, primary, Bao, Larry, primary, Ahdesmaki, Miika J., primary, Walker, Graeme, primary, O'Connor, Greg, primary, Yeh, Tammie C., primary, Rabow, Alfred A., primary, Dry, Jonathan R., primary, Reimer, Corinne, primary, Lyne, Paul, primary, Mills, Gordon B., primary, Fawell, Stephen E., primary, Waring, Michael J., primary, Zinda, Michael, primary, Clark, Edwin, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

159. Supplementary Table 1 from AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Author

Rhyasen, Garrett W., primary, Hattersley, Maureen M., primary, Yao, Yi, primary, Dulak, Austin, primary, Wang, Wenxian, primary, Petteruti, Philip, primary, Dale, Ian L., primary, Boiko, Scott, primary, Cheung, Tony, primary, Zhang, Jingwen, primary, Wen, Shenghua, primary, Castriotta, Lillian, primary, Lawson, Deborah, primary, Collins, Michael, primary, Bao, Larry, primary, Ahdesmaki, Miika J., primary, Walker, Graeme, primary, O'Connor, Greg, primary, Yeh, Tammie C., primary, Rabow, Alfred A., primary, Dry, Jonathan R., primary, Reimer, Corinne, primary, Lyne, Paul, primary, Mills, Gordon B., primary, Fawell, Stephen E., primary, Waring, Michael J., primary, Zinda, Michael, primary, Clark, Edwin, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

161. Development and validation of an inflammatory response-related gene and clinical factor-based signature for predicting prognosis in gastric cancer

Author

Li, Suihui, primary, Zhu, Jinfeng, additional, Zhu, Tengfei, additional, Xu, Yu, additional, Chen, Wenxi, additional, Zhou, Qiaoxia, additional, Wang, Guoqiang, additional, Li, Leo, additional, Han, Yusheng, additional, Xu, Chunwei, additional, Wang, Wenxian, additional, Cai, Shangli, additional, Xu, Ruilian, additional, and Shao, Yu, additional

Published
2023
Full Text
View/download PDF

162. Data from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Author

Wang, Zebin, primary, Grosskurth, Shaun E., primary, Cheung, Tony, primary, Petteruti, Philip, primary, Zhang, Jingwen, primary, Wang, Xin, primary, Wang, Wenxian, primary, Gharahdaghi, Farzin, primary, Wu, Jiaquan, primary, Su, Nancy, primary, Howard, Ryan T., primary, Mayo, Michele, primary, Widzowski, Dan, primary, Scott, David A., primary, Johannes, Jeffrey W., primary, Lamb, Michelle L., primary, Lawson, Deborah, primary, Dry, Jonathan R., primary, Lyne, Paul D., primary, Tate, Edward W., primary, Zinda, Michael, primary, Mikule, Keith, primary, Fawell, Stephen E., primary, Reimer, Corinne, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

163. Supplementary Figures from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Author

Wang, Zebin, primary, Grosskurth, Shaun E., primary, Cheung, Tony, primary, Petteruti, Philip, primary, Zhang, Jingwen, primary, Wang, Xin, primary, Wang, Wenxian, primary, Gharahdaghi, Farzin, primary, Wu, Jiaquan, primary, Su, Nancy, primary, Howard, Ryan T., primary, Mayo, Michele, primary, Widzowski, Dan, primary, Scott, David A., primary, Johannes, Jeffrey W., primary, Lamb, Michelle L., primary, Lawson, Deborah, primary, Dry, Jonathan R., primary, Lyne, Paul D., primary, Tate, Edward W., primary, Zinda, Michael, primary, Mikule, Keith, primary, Fawell, Stephen E., primary, Reimer, Corinne, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

164. Supplementary Materials from Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC

Author

Zhang, Kai, primary, Hong, Xiaohua, primary, Song, Zhengbo, primary, Xu, Yu, primary, Li, Chengcheng, primary, Wang, Guoqiang, primary, Zhang, Yuzi, primary, Zhao, Xiaochen, primary, Zhao, Zhengyi, primary, Zhao, Jing, primary, Huang, Mengli, primary, Huang, Depei, primary, Qi, Chuang, primary, Gao, Chan, primary, Cai, Shangli, primary, Gu, Feifei, primary, Hu, Yue, primary, Xu, Chunwei, primary, Wang, Wenxian, primary, Lou, Zhenkun, primary, Zhang, Yong, primary, and Liu, Li, primary

Published
2023
Full Text
View/download PDF

165. Supplementary tables from Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial

Author

Song, Zhengbo, primary, Lv, Dongqing, primary, Chen, Shi-Qing, primary, Huang, Jianjin, primary, Li, Yuping, primary, Ying, Shenpeng, primary, Wu, Xiaoyu, primary, Hua, Feng, primary, Wang, Wenxian, primary, Xu, Chunwei, primary, Bei, Ting, primary, Gao, Chan, primary, Sun, Zhijian, primary, Zhang, Yiping, primary, and Lu, Shun, primary

Published
2023
Full Text
View/download PDF

166. Supplementary table from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Author

Wang, Zebin, primary, Grosskurth, Shaun E., primary, Cheung, Tony, primary, Petteruti, Philip, primary, Zhang, Jingwen, primary, Wang, Xin, primary, Wang, Wenxian, primary, Gharahdaghi, Farzin, primary, Wu, Jiaquan, primary, Su, Nancy, primary, Howard, Ryan T., primary, Mayo, Michele, primary, Widzowski, Dan, primary, Scott, David A., primary, Johannes, Jeffrey W., primary, Lamb, Michelle L., primary, Lawson, Deborah, primary, Dry, Jonathan R., primary, Lyne, Paul D., primary, Tate, Edward W., primary, Zinda, Michael, primary, Mikule, Keith, primary, Fawell, Stephen E., primary, Reimer, Corinne, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

167. Supplemental Materials from Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer

Author

Wang, Zebin, primary, Grosskurth, Shaun E., primary, Cheung, Tony, primary, Petteruti, Philip, primary, Zhang, Jingwen, primary, Wang, Xin, primary, Wang, Wenxian, primary, Gharahdaghi, Farzin, primary, Wu, Jiaquan, primary, Su, Nancy, primary, Howard, Ryan T., primary, Mayo, Michele, primary, Widzowski, Dan, primary, Scott, David A., primary, Johannes, Jeffrey W., primary, Lamb, Michelle L., primary, Lawson, Deborah, primary, Dry, Jonathan R., primary, Lyne, Paul D., primary, Tate, Edward W., primary, Zinda, Michael, primary, Mikule, Keith, primary, Fawell, Stephen E., primary, Reimer, Corinne, primary, and Chen, Huawei, primary

Published
2023
Full Text
View/download PDF

168. Supplementary Figures from Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC

Author

Zhang, Kai, primary, Hong, Xiaohua, primary, Song, Zhengbo, primary, Xu, Yu, primary, Li, Chengcheng, primary, Wang, Guoqiang, primary, Zhang, Yuzi, primary, Zhao, Xiaochen, primary, Zhao, Zhengyi, primary, Zhao, Jing, primary, Huang, Mengli, primary, Huang, Depei, primary, Qi, Chuang, primary, Gao, Chan, primary, Cai, Shangli, primary, Gu, Feifei, primary, Hu, Yue, primary, Xu, Chunwei, primary, Wang, Wenxian, primary, Lou, Zhenkun, primary, Zhang, Yong, primary, and Liu, Li, primary

Published
2023
Full Text
View/download PDF

169. A pyroptosis-related gene signature for prognosis prediction in hepatocellular carcinoma

Author

Chen, Yongwei, primary, Zhu, Yanyun, additional, Dong, Yuanmei, additional, Li, Huizi, additional, Gao, Chumeng, additional, Zhu, Guoqiang, additional, Mi, Xiao, additional, Li, Chengcheng, additional, Xu, Yu, additional, Wang, Guoqiang, additional, Cai, Shangli, additional, Han, Yusheng, additional, Xu, Chunwei, additional, Wang, Wenxian, additional, Yang, Shizhong, additional, and Ji, Wenbin, additional

Published
2023
Full Text
View/download PDF

170. Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors

Author

Xu, Chunwei, primary, Zhang, Yongchang, additional, Wang, Wenxian, additional, Wang, Qian, additional, Li, Ziming, additional, Song, Zhengbo, additional, Wang, Jiandong, additional, Yu, Jinpu, additional, Liu, Jingjing, additional, Zhang, Shirong, additional, Cai, Xiuyu, additional, Wu, Ming, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Li, Jiancheng, additional, Liu, Baogang, additional, Yuan, Jingping, additional, Jiang, Zhansheng, additional, Lin, Gen, additional, Chen, Xiaohui, additional, Pu, Xingxiang, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Liu, Xuewen, additional, Wu, Jingxun, additional, Hu, Xiao, additional, Fang, Min, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Chen, Xiaofeng, additional, Pan, Weiwei, additional, Pang, Fei, additional, Zhou, Yuxiang, additional, Jian, Qijie, additional, Wang, Kai, additional, Wang, Liping, additional, Zhu, Youcai, additional, Yang, Guocai, additional, Lin, Xinqing, additional, Cai, Jing, additional, Liang, Lijun, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Huang, Jianhui, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Hao, Yue, additional, Wang, Zhen, additional, Wan, Bing, additional, Lv, Donglai, additional, Yu, Genhua, additional, Li, Anna, additional, Kang, Jin, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Chen, Huafei, additional, Shi, Lin, additional, Ye, Leiguang, additional, Wang, Gaoming, additional, Wang, Yina, additional, Gao, Feng, additional, Zhou, Wei, additional, Hu, Chunxiu, additional, Wei, Jianguo, additional, Li, Bihui, additional, Li, Zhongwu, additional, Li, Yuan, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Qiming, additional, Huang, Wenbin, additional, Hong, Zhuan, additional, Wang, Guansong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Zhu, Xixu, additional, Du, Kaiqi, additional, Ji, Jiansong, additional, Shen, Yi, additional, Zhang, Yiping, additional, Ma, Shenglin, additional, Song, Yong, additional, Lu, Yuanzhi, additional, Liu, Anwen, additional, Fang, Wenfeng, additional, and Zhong, Wenzhao, additional

Published
2023
Full Text
View/download PDF

173. A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma

Author

Hou, Jun, primary, Guo, Peng, additional, Lu, Yujiao, additional, Jin, Xiaokang, additional, Liang, Ke, additional, Zhao, Na, additional, Xue, Shunxu, additional, Zhou, Chengmin, additional, Wang, Guoqiang, additional, Zhu, Xin, additional, Hong, Huangming, additional, Chen, Yungchang, additional, Lu, Huafei, additional, Wang, Wenxian, additional, Xu, Chunwei, additional, Han, Yusheng, additional, Cai, Shangli, additional, and Liu, Yang, additional

Published
2023
Full Text
View/download PDF

174. An Affinity Propagation-Based Clustering Method for the Temporal Dynamics Management of High-Speed Railway Passenger Demand

Author

Wang, Wenxian, Shi, Tie, Zhang, Yongxiang, and Zhu, Qian

Subjects
Company business management, Algorithm, Passenger rail services -- Methods -- Analysis -- Traffic, High speed trains -- Methods -- Traffic -- Analysis, Algorithms -- Analysis -- Methods
Abstract

The number of passengers in a high-speed railway line normally varies significantly by the time periods, such as the peak and nonpeak hours. A reasonable classification of railway operation time intervals is essential for an adaptive adjustment of the train schedule. However, the passenger flow intervals are usually classified manually based on experience, which is subjective and inaccurate. Based on the time samples of actual passenger demand data for 365 days, this paper proposes an affinity propagation (AP) algorithm to automatically classify the passenger flow intervals. Specifically, the AP algorithm first merges time samples into different categories together with the passenger transmit volume of the stations, which are used as descriptive variables. Furthermore, clustering validity indexes, such as Calinski-Harabasz, Hartigan, and In-Group Proportion, are employed to examine the clustering results, and reasonable passenger flow intervals are finally obtained. A case study of the Zhengzhou-Xi'an high-speed railway indicates that our proposed AP algorithm has the best performance. Moreover, based on the passenger flow interval classification results obtained using the AP algorithm, the train operation plan fits the passenger demand better. As a result, the indexes of passenger demand satisfaction rate, average train occupancy rate, and passenger flow rate are improved by 7.6%, 16.7%, and 14.1%, respectively, in 2014. In 2015, the above three indicators are improved by 5.7%, 18.4%, and 14.4%, respectively., Author(s): Wenxian Wang (corresponding author) [1]; Tie Shi [2]; Yongxiang Zhang [3,4]; Qian Zhu [5] 1. Introduction With the extension and integration of China's high-speed railway network, it is becoming [...]

Published
2021
Full Text
View/download PDF

179. The combination of etoposide and platinum for the treatment of thymic neuroendocrine neoplasms: A retrospective analysis.

Author

Guan, Yelan, Yao, Qifeng, Hao, Yue, Zeng, Xiaohong, Wang, Wenxian, Gu, Xiadong, Xiang, Jing, Sun, Yan, and Song, Zhengbo

Subjects
NEUROENDOCRINE tumors, PLATINUM, ETOPOSIDE, MYELOSUPPRESSION, RETROSPECTIVE studies
Abstract

Background: To provide real‐world outcomes for the combination of etoposide and platinum as a first‐line treatment for advanced thymic neuroendocrine neoplasms (TNENs). Methods: Retrospective analysis was performed on patients with advanced TNENs confirmed by pathology who received etoposide combined with platinum as a first‐line chemotherapy in our institution between 2010 and 2022. Results: A total of 16 patients were included in this study. Twelve patients (75%) received etoposide combined with cisplatin, and four patients (25%) received etoposide combined with carboplatin. Efficacy was evaluated in all patients, with an objective response rate of 31.3%. One patient achieved a complete response, four achieved a partial response, and in eight patients the disease remained stable; the disease control rate was 81.3%. The median progression‐free survival (PFS) was 7.2 months with a 95% confidence interval (CI) of 2.1–12.3 months. The median overall survival (OS) was 50.4 months with a 95% CI of 32.1–68.8 months. No significant difference in efficacy was observed between the treatment groups with regards to PFS (p = 0.095) and OS (p = 0.061). Treatment‐related adverse events were observed in all 12 patients when evaluated for toxicity, manifesting as hematologic toxicity. Grade 3–4 bone marrow suppression occurred in six patients (50%). No treatment‐related deaths were recorded. Conclusion: This retrospective analysis, conducted in a real‐life setting, suggests that the combination of etoposide and platinum has a promising anti‐tumor activity in advanced TNENs, with a clinically significant overall response rate. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

181. A DNA Damage Response Related Signature to Predict Prognosis in Patients with Acute Myeloid Leukemia

Author

Wang, Jun, primary, Wu, Jiafei, additional, Wang, Yijing, additional, Wang, Yu, additional, Jiang, Chuanyan, additional, Zou, Mengying, additional, Jin, Xiaokang, additional, Sun, Xiaoran, additional, Zhang, Yu, additional, Ma, Sijia, additional, Wang, Guoqiang, additional, Zhu, Xin, additional, Lu, Huafei, additional, Xu, Chunwei, additional, Wang, Wenxian, additional, Li, Leo, additional, Han, Yusheng, additional, Cai, Shangli, additional, and Li, Hui, additional

Published
2023
Full Text
View/download PDF

195. Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer

Author

Zhang, Shirong, primary, Wang, Wenxian, additional, Xu, Chunwei, additional, Zhang, Yongchang, additional, Cai, Xiuyu, additional, Wang, Qian, additional, Song, Zhengbo, additional, Li, Ziming, additional, Yu, Jinpu, additional, Zhong, Wenzhao, additional, Wang, Zhijie, additional, Liu, Jingjing, additional, Liu, Anwen, additional, Li, Wen, additional, Zhan, Ping, additional, Liu, Hongbing, additional, Lv, Tangfeng, additional, Miao, Liyun, additional, Min, Lingfeng, additional, Lin, Gen, additional, Huang, Long, additional, Yuan, Jingping, additional, Jiang, Zhansheng, additional, Pu, Xingxiang, additional, Rao, Chuangzhou, additional, Lv, Dongqing, additional, Yu, Zongyang, additional, Li, Xiaoyan, additional, Tang, Chuanhao, additional, Zhou, Chengzhi, additional, Zhang, Junping, additional, Guo, Hui, additional, Chu, Qian, additional, Meng, Rui, additional, Liu, Xuewen, additional, Wu, Jingxun, additional, Zhou, Jin, additional, Zhu, Zhengfei, additional, Pan, Weiwei, additional, Dong, Xiaowei, additional, Pang, Fei, additional, Wang, Kai, additional, Yao, Chao, additional, Lin, Guomin, additional, Li, Site, additional, Yang, Zhi, additional, Luo, Jiancheng, additional, Jia, Hongtao, additional, Nie, Xiuqing, additional, Wang, Liping, additional, Zhu, Youcai, additional, Hu, Xiao, additional, Xie, Yanru, additional, Lin, Xinqing, additional, Cai, Jing, additional, Xia, Yang, additional, Feng, Huijing, additional, Wang, Lin, additional, Du, Yingying, additional, Yao, Wang, additional, Shi, Xuefei, additional, Niu, Xiaomin, additional, Yuan, Dongmei, additional, Yao, Yanwen, additional, Kang, Jing, additional, Zhang, Jiatao, additional, Zhang, Chao, additional, Gao, Wenbin, additional, Huang, Jianhui, additional, Zhang, Yinbin, additional, Sun, Pingli, additional, Wang, Hong, additional, Ye, Mingxiang, additional, Wang, Dong, additional, Wang, Zhaofeng, additional, Wan, Bing, additional, Lv, Donglai, additional, Yu, Genhua, additional, Shi, Lin, additional, Xia, Yuanli, additional, Gao, Feng, additional, Zhang, Xiaochen, additional, Xu, Tao, additional, Zhou, Wei, additional, Wang, Haixia, additional, Liu, Zhefeng, additional, Yang, Nong, additional, Wu, Lin, additional, Wang, Qiming, additional, Wang, Guansong, additional, Hong, Zhuan, additional, Wang, Jiandong, additional, Fang, Meiyu, additional, Fang, Yong, additional, Zhang, Yiping, additional, Song, Yong, additional, Ma, Shenglin, additional, Fang, Wenfeng, additional, and Lu, Yuanzhi, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results